Guangdong Hengrui Pharmaceutical Co., Ltd
PharmaGuangzhou, Guangdong, China · Est. 2000
Guangdong Hengrui Pharmaceutical is a Chinese biopharmaceutical company focused on the research, development, and commercialization of innovative drugs.
8
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
12
Indications↗
Distinct diseases across all programs
66
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
8 drugs in development
Phase 34
Phase 25
Phase 12
By Therapeutic Area
top 5
Respiratory
538%
Immunology
431%
Dermatology
18%
Nephrology
18%
Hematology
18%
R&D Momentum
69/100
Pipeline Velocity
52/100
Trial Completion Rate
96/100
Pipeline Concentration
27/100
Pipeline Freshness
91/100
Strategic Signals
- ↗Active in Dermatology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Sep 10, 2026
Completed
A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics for a Single Dose of HRS-9821 Powder for Inhalation and Inhalation Suspension Administered in Healthy Subjects and Multiple Doses in Patients With COPD.
Sep 9, 2026
Recruiting
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study Evaluating the Efficacy and Safety of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis
Earlier
Sep 4, 2026TrialA Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of SHR-1819 Injection in Patients With Moderate to Severe Atopic Dermatitis
Sep 1, 2026TrialA Study on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SHR-7012 in Healthy Adults
Aug 28, 2026TrialA Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis
Aug 25, 2026TrialA Randomized, Open-Label, Parallel-Group Clinical Study to Evaluate the Bioavailability and Safety of Subcutaneous SHR-1819 Injection Administered Using Different Injection Devices in Healthy Subjects
Aug 21, 2026TrialA Multicenter, Randomized, Double-blind, Parallel-group Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-1139 Injection in Patients With Moderate to Severe Plaque Psoriasis
Aug 19, 2026TrialA Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of HRS-9821 Inhalation Suspension in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
3 more events
Aug 18, 2026TrialA Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis
Aug 12, 2026TrialA Multicenter, Randomized, Double-blind, Dose-parallel-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-1139 Injection in Patients With Plaque Psoriasis Who Have Poor Response to Biological Agents
Aug 12, 2026TrialA Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR-7590 Via Subcutaneous or Intravenous Administration in Chinese Healthy Participants and Patients With Moderate-to-Severe Ulcerative Colitis
Details
Company Info
Therapeutic Focus
OncologyCardiovascularAnti-infection
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Dermatology
Immunology
Respiratory
Unknown / Other
Dermatology
Prurigo Nodularis
SHR-1819Phase 3
Immunology
Nephrology
Respiratory
Pulmonary Fibrosis
HRS-9813Phase 2
Unknown / Other
Drug Interactions
HRS-9813Phase 1
Showing 15 of 16 programs
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)